Diabetes drug lowers BP without changing salt in urine
Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Blood pressure dropped significantly without changes in sodium excretion
The medical community assumed SGLT2 inhibitors lowered BP by increasing salt excretion, but this study found no such link despite controlled sodium intake.
Practical Takeaways
Patients on SGLT2 inhibitors may see BP benefits regardless of salt intake
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Blood pressure dropped significantly without changes in sodium excretion
The medical community assumed SGLT2 inhibitors lowered BP by increasing salt excretion, but this study found no such link despite controlled sodium intake.
Practical Takeaways
Patients on SGLT2 inhibitors may see BP benefits regardless of salt intake
Publication
Journal
Diabetes Care
Year
2020
Authors
R. Scholtes, M. Muskiet, Michiel J.B. van Baar, Anne C. Hesp, P. Greasley, C. Karlsson, A. Hammarstedt, Nikita Arya, D. V. van Raalte, Hiddo J. L. Heerspink
Related Content
Claims (9)
After starting dapagliflozin, the kidneys produced more aldosterone hormone for a few days, which might help the body retain salt, but this effect didn't last after two weeks.
Taking dapagliflozin for two weeks lowered blood pressure by about 6-7 points in people with type 2 diabetes and healthy kidneys, even when they ate a controlled amount of salt.
Even though dapagliflozin lowered blood pressure, it didn't cause people with type 2 diabetes and healthy kidneys to excrete more salt in their urine when they ate a controlled amount of salt.
Dapagliflozin caused a temporary decrease in body fluid volume outside cells after 4 days, but this effect went away after two weeks in people with type 2 diabetes and healthy kidneys.
Dapagliflozin didn't significantly change the amount of fluid in the bloodstream of people with type 2 diabetes and healthy kidneys, even after two weeks of treatment.